Pay in 4 interest-free payments of $6.18 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Currently, drugs that are approved solely for obesity treatment have minimal to no coverage on ACA Marketplace plans
Instead, under the discovery rule, the two-year filing window only begins on the date the plaintiff discovered, or reasonably should have discovered, that the product might have caused their injury
Zepbound is approved for adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related health condition and should be used alongside a reduced-calorie diet and increased physical activity
Chronic is the operative word: it is designed and labeled for ongoing, long-term use, consistent with treating obesity as a chronic disease
Freezing or exposing the medication to temperatures above 46F can break down the active ingredient and render it less effective
The company references FSA and HSA payment eligibility and a cash-pay model in its published materials
